Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps

This study aims to evaluate the safety and effectiveness of Xolair® in patients with chronic rhinosinusitis with nasal polyps in routine clinical practice.

Inclusion Criteria:Adults aged ≥18 yearsPatients with CRSwNP who are not adequately controlled with conventional therapy (INCS)Patients prescribed with Xolair® as per the locally approved label information.Patients who provide written informed consent to participate in the studyExclusion Criteria:Patients who do not provide consent to participate in the studyPatients participating in other clinical trialContraindications listed in the locally approved label information of Xolair®Hypersensitivity to the active ingredient or any other ingredient of Xolair®Patients with myocardial infarction or history of myocardial infarction (pre-filled syringes only)